| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Leptophylloside have not been well-characterized in the published literature. As a psoralen derivative, it may interact with DNA through intercalation and, upon ultraviolet (UVA) irradiation, form covalent adducts with pyrimidine bases, leading to DNA cross-linking and inhibition of DNA synthesis. This mechanism is responsible for the phototoxic and photosensitizing effects of psoralens and is the basis for their use in PUVA therapy for skin disorders. In addition to its DNA interactions, Leptophylloside may have antioxidant or anti-inflammatory activities, as other psoralen derivatives have been reported to possess these properties. However, the specific targets and mechanisms of action of Leptophylloside require further investigation.
|
|---|---|
| ln Vitro |
In vitro, Leptophylloside has been studied for its potential cytotoxic activity against cancer cell lines. However, specific data on its in vitro potency and activity are limited. As a psoralen glycoside, it may exhibit phototoxicity in cell culture when exposed to UVA light. In the absence of UVA irradiation, the compound may have minimal cytotoxic effects. Its antioxidant activity, if any, would be assessed using standard cell-free or cell-based antioxidant assays. The compound's glycosidic moiety may affect its cellular uptake and activity compared to the aglycone psoralen. Further studies are needed to fully characterize the in vitro biological activities of Leptophylloside.
|
| ln Vivo |
In vivo, the biological activities of Leptophylloside have not been extensively studied. As a naturally occurring psoralen glycoside, it may be metabolized to the aglycone psoralen, which could then exert phototoxic or other effects. However, the compound's in vivo pharmacokinetics, metabolism, and pharmacological effects have not been well-documented in the available literature. Leptophylloside has been reported in various plant species, suggesting that it may contribute to the biological properties of these plants, but its specific role and efficacy in vivo remain to be determined.
|
| Enzyme Assay |
The non-cellular assay for Leptophylloside, if performed, would likely involve the measurement of its phototoxic activity or its ability to interact with DNA. In a typical psoralen-DNA interaction assay, the compound is incubated with calf thymus DNA in the presence or absence of UVA irradiation. The formation of DNA adducts is monitored by changes in UV absorbance, fluorescence, or by gel electrophoresis. The compound's ability to inhibit DNA synthesis or to cross-link DNA can be assessed. In addition, the compound's antioxidant activity can be measured using cell-free assays such as DPPH radical scavenging or ABTS assays. However, specific experimental protocols for Leptophylloside have not been published.
|
| Cell Assay |
The cellular assay for Leptophylloside would involve testing its phototoxicity or cytotoxicity in cultured cells. Cells are treated with Leptophylloside at various concentrations, either in the dark or with exposure to UVA light. Cell viability is assessed using standard assays such as MTT or trypan blue exclusion. The phototoxic index (the ratio of cytotoxicity with UVA exposure to cytotoxicity without UVA exposure) is calculated to quantify the compound's phototoxic potential. In addition, the effects of Leptophylloside on cell cycle progression, apoptosis, and DNA damage (as assessed by comet assay or γ-H2AX staining) can be studied. These assays are standard for evaluating psoralen derivatives.
|
| Animal Protocol |
In vivo animal studies for Leptophylloside have not been well-documented in the available literature. As a naturally occurring compound, it may be studied in models of photodermatology or in models of the conditions for which psoralens are used, such as psoriasis or vitiligo. However, specific protocols and findings have not been reported.
|
| ADME/Pharmacokinetics |
Leptophylloside has a molecular weight of 424.40 g/mol and a molecular formula of C₂₀H₂₄O₁₀. It is a solid compound that is soluble in organic solvents. The compound is a glycosylated psoralen, which may affect its solubility, stability, and bioavailability compared to the aglycone. Its pharmacokinetic properties have not been characterized. Leptophylloside should be stored in a cool, dry place, protected from light, as psoralens are light-sensitive compounds.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Leptophylloside has not been extensively characterized. As a psoralen derivative, it is expected to have phototoxic potential, meaning that it can cause skin irritation and damage upon exposure to UVA light. This is a well-known property of psoralens and is the basis for their therapeutic use in PUVA therapy, but also for their side effects, including phototoxicity and an increased risk of skin cancer with long-term use. The compound should be handled with care, avoiding exposure to UV light, and appropriate personal protective equipment should be used.
|
| References | |
| Additional Infomation |
Psoralen compounds contain folioside. Reports have indicated that rue and Corsican rue contain folioside, and relevant data are available for reference.
Leptophylloside (Isorutarin) is a naturally occurring furanocoumarin glycoside that belongs to the psoralen class of compounds. It is found in various plant sources, including celery, Peucedanum praeruptorum, and Ruta graveolens. As a psoralen derivative, it is of interest for its potential phototoxic and photosensitizing properties, which are the basis for the therapeutic use of psoralens in skin disorders. However, the specific biological activities and pharmacological potential of Leptophylloside have not been extensively characterized, and further research is needed to fully understand its properties and potential applications. |
| Molecular Formula |
C20H24O10
|
|---|---|
| Molecular Weight |
424.4
|
| Exact Mass |
275.152
|
| CAS # |
53846-51-8
|
| PubChem CID |
185756
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.59g/cm3
|
| Boiling Point |
690.7ºC at 760mmHg
|
| Flash Point |
245.1ºC
|
| Index of Refraction |
1.673
|
| LogP |
2.348
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
681
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C)(C1CC2=C(O1)C(=C3C(=C2)C=CC(=O)O3)O)OC4C(C(C(C(O4)CO)O)O)O
|
| InChi Key |
QZUDEXAHKXCIDG-NUUDRHLNSA-N
|
| InChi Code |
InChI=1S/C20H24O10/c1-20(2,30-19-15(25)14(24)13(23)10(7-21)27-19)11-6-9-5-8-3-4-12(22)29-17(8)16(26)18(9)28-11/h3-5,10-11,13-15,19,21,23-26H,6-7H2,1-2H3/t10-,11-,13-,14+,15-,19+/m1/s1
|
| Chemical Name |
(2R)-9-hydroxy-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one
|
| Synonyms |
Isorutarin; Leptophylloside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3563 mL | 11.7813 mL | 23.5627 mL | |
| 5 mM | 0.4713 mL | 2.3563 mL | 4.7125 mL | |
| 10 mM | 0.2356 mL | 1.1781 mL | 2.3563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
